Claims

1. The compound: *N*-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide:



or a pharmaceutically acceptable salt thereof.

2. The compound: *N*-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide, as claimed in claim 1.

3. A pharmaceutically acceptable salt as claimed in claim 1, which is the mesylate salt of *N*-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide.

4. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3, in association with a pharmaceutically acceptable diluent or carrier.

5. The compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use as a medicament.

6. The compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use in the treatment of cancer.

7. The compound or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, for use in the treatment of non-small-cell lung cancer.

8. The use of the compound or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 3, for the manufacture of a medicament for the treatment of cancer.

9. The use as claimed in claim 8, wherein the cancer is non-small-cell lung cancer.

Claims

1. The compound N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide:

or a pharmaceutically acceptable salt thereof.

2. The compound N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide according to claim 1.

3. A pharmaceutically acceptable salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide according to claim 1.

4. A pharmaceutically acceptable salt according to claim 1, which is the mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide.

5. A pharmaceutical composition containing a compound or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 4, in association with a pharmaceutically acceptable diluent or carrier.

6. A medicament containing a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

7. A medicament according to Claim 6, for use in the treatment of cancer.

8. A medicament according to Claim 7, wherein the cancer is non-small cell lung cancer.

9. Use of a compound or pharmaceutically acceptable salt according to any one of Claims 1 to 4, for the production of a medicament for the treatment of cancer.

10. Use according to Claim 9, wherein the cancer is non-small cell lung cancer.